Literature DB >> 15019299

Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation.

Hélène Legros1, Marie-George Dingeval, François Janin, Jean Costentin, Jean-Jacques Bonnet.   

Abstract

3,4-Dihydroxyphenylacetaldehyde (DOPAL) is formed by the oxidative deamination of dopamine (DA) catalyzed by monoamine oxidases (MAO); then, the aldehyde is oxidized to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenases (ALDH) or reduced to 3,4-dihydroxyphenylethanol (DOPET) by aldose/aldehyde reductases. The present work aimed at evaluating the in vitro toxicity of DOPAL on catecholaminergic neuroblastoma SH-SY5Y cells which accumulate DA. DOPAL synthesis was stimulated by incubating cells with DA and blocking DOPAL oxidation by disulfiram, an irreversible inhibitor of ALDH. As evidenced by MTT reduction assays, DA and disulfiram treatments produced cell losses which increased with time. 10(-2)M DA reduced by 40% cell viability after a 1h treatment, when its TC(50) (concentration reducing viability by 50%) value was 7.3 x 10(-5) M after a 24 h treatment. For the same treatment periods, TC(50) values for disulfiram were 8 x 10(-5) and 8.7 x 10 (-7) M, respectively. MTT reduction assay performed after a 24h treatment followed by a 24h incubation in a drug-free medium evidenced that the toxicity of 10(-4)M DA or 10(-6)M disulfiram was potentiated by the second drug. HPLC measurements showed that DOPAL was produced at the early stages of the treatment by DA and disulfiram. This was evidenced by the significant increase in the ((DOPAL + DOPET)/DOPAC ratio observed after a combined 3h treatment by 10(-4)M DA and 10(-6)M disulfiram. Total contents in DA and DOPAL were greatly reduced at the end of a 15 h treatment, and disulfiram did not significantly enhanced the (DOPAL + DOPET)/DOPAC ratio. For both treatment durations, DOPAL and DOPET were detectable only in the extracellular medium. So, these results suggest that an early production of DOPAL could produce delayed toxic effects on SH-SY5Y cells. Production of DOPET and release of DOPAL could be important means for reducing DOPAL concentrations in dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019299     DOI: 10.1016/S0161-813X(03)00148-7

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  12 in total

1.  Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease.

Authors:  Elizabeth A Sabens Liedhegner; Kelly M Steller; John J Mieyal
Journal:  Chem Res Toxicol       Date:  2011-08-22       Impact factor: 3.739

2.  Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde.

Authors:  Courtney Holmes; Noel Whittaker; Jorge Heredia-Moya; David S Goldstein
Journal:  Clin Chem       Date:  2010-03-05       Impact factor: 8.327

3.  Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson's disease.

Authors:  Elizabeth A Sabens; Anne M Distler; John J Mieyal
Journal:  Biochemistry       Date:  2010-03-30       Impact factor: 3.162

Review 4.  Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease.

Authors:  Edna Grünblatt; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2014-10-09       Impact factor: 3.575

5.  Modulation of aldehyde dehydrogenase activity affects (±)-4-hydroxy-2E-nonenal (HNE) toxicity and HNE-protein adduct levels in PC12 cells.

Authors:  Dehe Kong; Vinayaka Kotraiah
Journal:  J Mol Neurosci       Date:  2011-12-15       Impact factor: 3.444

6.  Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Rachel Sullivan; Daniel J Gross; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2012-10-25       Impact factor: 5.372

7.  DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.

Authors:  N Plotegher; G Berti; E Ferrari; I Tessari; M Zanetti; L Lunelli; E Greggio; M Bisaglia; M Veronesi; S Girotto; M Dalla Serra; C Perego; L Casella; L Bubacco
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

Review 8.  Impaired dopamine metabolism in Parkinson's disease pathogenesis.

Authors:  Anna Masato; Nicoletta Plotegher; Daniela Boassa; Luigi Bubacco
Journal:  Mol Neurodegener       Date:  2019-08-20       Impact factor: 14.195

9.  Stable expression of the human dopamine transporter in N27 cells as an in vitro model for dopamine cell trafficking and metabolism.

Authors:  B S Cagle; M L Sturgeon; J B O'Brien; J C Wilkinson; R A Cornell; D L Roman; J A Doorn
Journal:  Toxicol In Vitro       Date:  2021-07-05       Impact factor: 3.685

10.  Monoamine oxidase-A promotes protective autophagy in human SH-SY5Y neuroblastoma cells through Bcl-2 phosphorylation.

Authors:  Aslihan Ugun-Klusek; Theodosis S Theodosi; Julia C Fitzgerald; Florence Burté; Christoph Ufer; David J Boocock; Patrick Yu-Wai-Man; Lynn Bedford; E Ellen Billett
Journal:  Redox Biol       Date:  2018-10-09       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.